Talphera Inc. (TLPH)
TLPH trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1427925/000143774926009387/0001437749-26-009387-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TLPH on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2011 |
| SEC CIK | 0001427925 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $28K |
| Net income | -$14.3M |
| Operating income | -$13.5M |
| Net margin | -51035.7% |
| Operating margin | -48157.1% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $5.9M |
| Total assets | $29.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1597.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $10.7M cash; operating cash flow -$3.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 51,957,714 (2026-11-04); 46,609,618 a year earlier; 16,952,269 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-12 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-03-13 |
| Auditor | BPM LLP, Walnut Creek, California, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $276K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$4.0M | -$3.0M | $10.7M | No debt tags | $0 | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $0 | -$4.3M | -$3.9M | $742K | No debt tags | $1K | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $0 | -$2.6M | -$3.4M | $3.8M | No debt tags | $1K | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $0 | -$3.8M | -$2.4M | $5.9M | No debt tags | $28K | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | $1K | -$4.4M | -$2.5M | $3.5M | No debt tags | $28K | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $0 | -$3.5M | -$2.9M | $6.8M | No debt tags | $27K | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $27K | -$2.6M | -$3.5M | $5.4M | No debt tags | $27K | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $0 | -$1.9M | -$2.3M | $8.9M | No debt tags | $0 | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2026-11-12 |
| Latest annual report FORM 10-K | 10-K | 2026-03-23 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 966 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.3% |
| 1 month | -15.0% |
| 3 months | -24.8% |
| Year to date | -20.2% |
| 1 year | -13.3% |
| From 52-week high | -38.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HYFT | MindWalk Holdings Corp. | $0.9378 | -8.95% | $44.6M |
| ONCY | Oncolytics Biotech Inc. | $0.3399 | -8.14% | $44.6M |
| NMAD | Nomad Power Solutions Inc. | $2.80 | +19.15% | $45.1M |
| MIST | Milestone Pharmaceuticals Inc. Common Shares | $0.3650 | -29.81% | $45.4M |
| RNXT | RenovoRx Inc. | $0.9549 | -8.18% | $46.1M |
| ANVS | Annovis Bio Inc. | $0.7500 | -19.02% | $46.5M |
| PLRX | Pliant Therapeutics Inc. | $0.6932 | -0.55% | $43.0M |
| ATNM | Actinium Pharmaceuticals Inc. (Delaware) | $1.49 | -9.15% | $46.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier